Lars Wood, CEO/Co-founder; LinkedIn

Lars Wood is a pioneer in high performance computing, machine learning (8 patents), EHF analog mixed signal integrated circuits and algorithms, solver intractable challenges for DoD and industry through novel invention, development and application of hw and sw systems since the early 1980’s.

Lars has built a diverse career in AI, machine learning, novel algorithms, quantum physics, therapeutic small molecule drug discovery, ab initio quantum chemistry, brain cancer fundamental mechanism basic research, microelectronic, optoelectronic, superconducting and analog and hybrid VLSI design, extremely low temperature and semiconductor solid state physics including quantum computing research. He was the founder and director of a $21M Advanced Machine Intelligence Laboratory and is responsible for the first large scale ANN $712M program.

In 1993 he designed and built the first optoelectronic FCCM machine, which was presented at the first IEEE conference on field reconfigurable computing. The NSA and Intel invited IEEE paper he published on the machine is considered the vision reference for all FCCM computing.

His QAI SPECTRE™ super Turing machine is a recurrent analog neural network exceeding P-Space reducible digital and quantum computation via self-organized analog real number device implementation unified neural processing/connectionist memory. QAI SPECTRE™ is a GaAs and GaN 4D MCM-D on micro cooled diamond. It’s analog neurons operate at 3 THz+ unclocked frequency. It’s neurons are are wireless with dynamic semiconductor interconnect. 

QAI SPECTRE™ neurons are implemented through foundry process modification of semiconductor neuron metal gate foot physical structure to implement dynamic very high fan in and fan out neuron sub millimeter wave network and die connectivity. QAI SPECTRE™ modules require 1J (1W) of energy. QAI SPECTRE™ module recurrent neural network performance exceeds 500 Quadrillion operations per sec.

View Lars’ patents here (for 8 past patents) and here for a recent neural network patent.

Lisa Wood, Co-Founder; LinkedIn

Lisa Wood is an entrepreneur inspired by novel science and technology, specifically, artificial intelligence transformation globally. Lisa has been involved in AI for 2 decades at different levels, resulting in QAI (Quantum Artificial Intelligence). Lisa's longtime involvement in media, on the tech front, includes Fortune, BusinessWeek and now Forbes. Lisa founded Cognitive World, a growing AI knowledge hub, ecosystem and marketplace to optimize our global journey to AI transformation ~ for AI dealmakers.

Lars Wood note: Lisa Wood is the driving force behind QAI LLC. She was the first investor and believer in the technology, which is now reduced to practice as the first super Turing neural machine technology. Without Lisa, Lars Wood would still be modeling thermonuclear weapons using lattice gas methods or designing novel supercomputers for the US military and its classified agencies.


Mike DeFazio has been a long-time supporter of Lars Wood (since 2001). Mr. DeFazio is a retired executive with a 30-year career in the software industry, 15 years as a senior executive with a number of companies. During his career, Mike had product development and marketing responsibilities in both public and private companies including EVP at Novell's UNIX business and President of UNIX Systems Laboratories. Prior to joining UNIX he held a variety of positions at AT&T and Bell Labs. Mr. DeFazio advises early stage infrastructure and software companies.

Eric Ellingson, Advisor

Eric Ellingson, Advisor

Eric Ellingson was a colleague of English Mathematician Gordon Welchman, Director of Bletchley Park. Mr. Ellingson was the Technical Director of The MITRE Corporation and system architect of the Joint Tactical Information Distribution System. He is a mentor and senior special advisor to QAI CEO Lars Wood and to the QAI SPECTRE™ program.

Chuck Brooks, Advisor;    LinkedIn

Chuck Brooks, Advisor;

Chuck Brooks is a thought leader, influencer and technology evangelist in cybersecurity. He is Principal Market Growth Strategist, Cybersecurity and Emerging Technologies for General Dynamics Mission Systems.

Chuck is named by Thompson Reuters as a “Top 50 Social Influencer in Risk, Compliance”; is named by IFSEC as “#2 Global Cybersecurity Influencer; is a two-time Presidential Appointee for Executive Service; is a Top Person To Follow on Tech by LinkedIn; Helped "stand up" Office of Legislative Affairs at the US Department of Homeland Security; Served as first Director of Legislative Affairs at the DHS Science & Technology Directorate; Served as Senior Legislative Staff (foreign affairs, security, tech, business) to Senator Arlen Specter, U.S. Senate; Adjunct Faculty at Georgetown University and former Adjunct Faculty Johns Hopkins University; Former Technology Partner Advisor at Bill and Melinda Gates Foundation; Judge; Government Security News Homeland Security Awards; Published over 175 articles on technology and cybersecurity topics; Member of The #CyberAvengers, and Cyber Start Up Observatory Hall of Fame.

Chuck is a featured writer and speaker on homeland security, cyber security, CBRNE, AI, science & technology, public/private partnerships, IoT, innovation. He is published in FORBES, Huffington Post, InformationWeek, MIT Sloan Blog, Computerworld, Federal Times, NextGov, Government Security News, Cygnus Security Media, Homeland Security Today (visiting editor), The Hill, Biometric Update, Bizcatalyst360, IT Security Planet, Christian Science Monitor and Cognitive World.

Jayshree Pandya, Ph.D., Advisor;    LinkedIn

Jayshree Pandya, Ph.D., Advisor; LinkedIn

Jayshree Pandya, PhD., (née Bhatt), Founder and CEO of Risk Group LLC, is a scientist, a visionary, a futurist, an expert in disruptive technologies, and a globally recognized strategic security risk intelligence expert with decades of experience in science and technology, technology trends, digital disruption, strategic security risks, and nation preparedness.

Her doctorate work focused on hydrogen production by Halobacterium halobium, for which she received India’s National Young Scientist Award in Biochemistry. Her publications on this work have been cited in several books, journals, and reports published by governments, including a report from the United States Department of Energy[1]. Her work on anti-cancer drugs also received worldwide attention and, amongst other citations, has been referenced in a report published by the World Health Organization[2].

In 1991, she was invited to come to United States (under the Scientist Exchange Program) to continue research on hydrogen production and was awarded a post-doctoral fellowship at the Hawaii Natural Energy Institute. In 1992 she researched atherosclerosis at the University of Chicago Medical School. Next, she took a job at Aurotech, a biotech company based in Wisconsin. As in her PhD research, she used microorganisms to develop natural processes and technologies, and some of the projects she worked on were quite promising. While her doctorate and post-doctorate studies gave her the first taste of the power of interdisciplinary research, it also introduced her to the repressive power of institutional silos and inefficiencies. As a result, her physical location wasn’t the only thing that shifted in the 1990s; her focus did as well. Since Microbiology trained her to see changes in tiny organisms coming from natural selection, she began to see similar forces at work in the evolution of individuals as well as entities across nations: its government, industries, organizations and academia (NGIOA) and society in general. It’s all the same basic mechanism. Her career took another turn after she was asked to consider risk management as part of a strategic planning effort by one of her employers. She quickly realized that most risk management is all process, with no actual benefit. That was the beginning of Risk Group, the strategic security risk research organization she founded in 2002, where she is passionately creating and managing cutting-edge security ventures that bring a futurist perspective to nations and all its components to improve innovation capacity, and define and design new ideas, innovations, products and services for security and sustainability.

A globally recognized thought leader and influencer, Jayshree is actively engaged in driving the thought leadership on existing and emerging technologies, technology transformation and nation preparedness. From National Science Foundation to organizations from across nations, Jayshree is an invited speaker on emerging technologies, technology transformation, digital disruption, strategic security risks, industry risks to country risks. She is the author of the book, The Global Age: NGIOA @ Risk

[1] Review of Non-conventional Bioreactor technology by C, E Turick and M.E Mcllwain Prepared for the US Dept of Energy. Published September 1993

[2] Palladium Environmental Health Criteria 226 prepared by Christine Melber, Dr. Detlef Keller and Dr. Inge Mengelsdrof Published by World Health Organization 2002

Alex Kiselyov, Ph.D., Advisor

Alex Kiselyov, Ph.D., Advisor

Alex Kiselyov, Ph.D. oversees all aspects of chemical genomics, biophysics, structural biology, target ID/validation and systems biology relevant to pluripotency, differentiation, proliferation of stem cells and diseases associated with deregulated neuromuscular junction. He contributes to chemistry aspects of clinical media development, disease modeling and cGMP of stem cell-based therapy. Alex’s key interests include innovative approaches to treating neurodegenerative, orphan diseases and cancer with specific focus on cancer cells quiescence and immunology. In his spare time, Alex follows research on the origins of Life and chirality.

Alex completed his Doctorate at Georgia State University in Atlanta followed by postgraduate studies at the Ben May Institute for Cancer Research (University of Chicago) and Columbia University (New York). He is a member of the Scientific Advisory Board for the Alzheimer’s Drug Discovery Foundation (New York). Alex holds an Adjunct Professor positions at the Moscow Institute of Physics and Technology (Biophysics and Molecular Biology).

 Alex Kiselyov has over 20 years of Pharma/Biotech and Foundation experience in drug discovery and preclinical development. He has directly contributed to over 10 clinical programs across multiple therapeutic areas including oncology, cardiovascular disease, dementias and cognitive disorders, rare diseases including Spinal Muscular Atrophy and Facioscapulohumeral Dystrophy (FSHD).

Through his professional career, Alex worked with multidisciplinary teams on the discovery of innovative therapies and diagnostic tools for Huntington’s disease (tomography probes (PET), anti-sense oligonucleotides, siRNAs and small molecules affecting mutant Huntingtin transcription and translation). He held positions of increasing responsibilities with Amgen, ImClone/Lilly, deCODE, CHDI Foundation, ChemDiv, Genea BioCells. Alex built and managed research teams (40-200 FTEs and multi-modal outsourcing) spanning target ID/validation, in vitro and ex vivo high-throughput-phenotypic- and high-content screening, structure-based drug discovery (biophysics, crystallography), medicinal/process chemistry, in vivo studies (PKPD/tox), CMC/regulatory, Phase I-II clinical interface, back-up programs. He contributed to/authored   > 170 peer-reviewed publications, 7 book chapters and over 50 awarded patents and patent applications.